**Gastroenterology Therapies**Referring Physician Orders Rev. 03.2025
Please fax completed referral form & all required documents to 208-595-4427



	PATIENT D	EMOGRAPH	IICS				
Patient Name:	DOB:		Phone:	:			
Address:	City/ST/Zip:						
Allergies:		□ NKDA	Weight:	□ lbs □ k	g Height: □ in □ cm		
	INSURANCE INFORMATION: Pleas	se attach copy c	of insurance card (	front and back).			
	DIA	AGNOSIS*					
	e (K50.00-K50.919), ICD10	□ Othe	r:		, ICD10		
Required Ulcerative Colit	is (K51.00-K51.919), ICD10						
	INFUS	ION ORDER	S				
MEDICATION	DOSE	DIRECTIONS	S/DURATION				
Cimzia® (certolizumab pegol) 400mg		☐ INITIAL: Inject 400mg SUBQ at Weeks 0, 2, 4, then every 4 weeks x 1 year ☐ MAINTENANCE: Inject 400mg SUBQ every 4 weeks x 1 year					
Entyvio® (vedolizumab) 300mg		☐ INITIAL: Infuse IV over 30 minutes at Weeks 0, 2, 6, then every 8 weeks x 1 year ☐ MAINTENANCE: Infuse IV over 30 minutes every 8 weeks x 1 year					
Infliximab and biosimilars:	□ mg (5 mg/kg)						
<ul> <li>□ Avsola<sup>®</sup></li> <li>□ Remicade<sup>®</sup></li> <li>□ Inflectra<sup>®</sup></li> <li>□ Renflexis<sup>®</sup></li> </ul>	□ mg (10 mg/kg) □ mg ( mg/kg)	<ul> <li>□ MAINTENANCE: Infuse IV over 2 hours every 8 weeks x 1 year</li> <li>□ MAINTENANCE: Infuse IV over 2 hours every weeks x 1 year</li> </ul>					
Omvoh™ (mirikizumab)	☐ CD: Infuse 900mg IV over 90 minutes every 4 weeks x 3 doses						
	☐ 300mg (for UC)	☐ UC: Infuse 300mg IV over 30 minutes every 4 weeks x 3 doses					
Skyrizi <sup>®</sup> (risankizumab) ☐ 600mg (for CD) ☐ 1200mg (for UC)		☐ CD: Infuse 600mg IV over 1 hour every 4 weeks x 3 doses ☐ UC: Infuse 1200mg IV over 2 hours every 4 weeks x 3 doses					
Stelara® (ustekinumab)	INITIAL IV Dose:  ☐ <55kg — 260mg ☐ 55kg to 85kg — 390mg ☐ >85kg — 520mg	☐ Infuse IV over 1 hour x 1 dose					
Tremfya® (guselkumab)	200mg	☐ Infuse IV over 1 hour every 4 weeks x 3 doses					
Tysabri® (natalizumab)  □ Patient enrolled in TOUCH Prescribing Program  300mg □ Infuse IV over 1 hour every 4 weeks x months  *Observe patient for 1 hour after completion of infusion.* □ If no hypersensitivity reaction observed with first 12 infusions, then post- infusion observations as directed by MD.							
Is patient currently receiving the	erapy above from another facility			Date c	of next treatment:		
		ER ORDERS					
LAB ORDERS: Labs to be dra		☐ Referring Phy					
□ No labs ordered at this time	q □ CRP q			LFTs q	□ Other:		
PRE-MEDICATION ORDERS:  ☐ No premeds ordered at this tii ☐ Acetaminophen 650mg PO ☐ Other:	EATION ORDERS: meds ordered at this time ninophen 650mg PO			☐ Diphenhydramine 25mg PO ☐ Methylprednisolone 40mg IVP -OR- ☐ Hydrocortisone 100mg IV			
	REFERRING PH	YSICIAN INF	ORMATION				
Physician Signature:				Date:			
	Physician Name: Provider NPI: Address:						
Contact Person:							
Email Where Follow Up Documentation				ιαλ π.			
Email Where I ollow op Boddmentatio	REQUIRED CLIN	ICAL DOCU	MENTATION				
Diagon attack modical recov	rds: Initial H&P, current MD progr				culto to cumpart diagnosis		
Test Results (required)  TB Screening for Cimzia, Entyvio, int  Annual TB screening to be Hepatitis B Screening for Cimzia and JC virus (JCV) antibody testing for T  Continuation labs to be d  Prior Failed Therapies (including	fliximab biosimilars, Omvoh, Skyrizi, Stela be done by:  Infusion Center Infliximab biosimilars (submit results to stysabri (submit results to start therapy and one by:  Infusion Center Influsion Center Influsi	ra and Tremfya (s  Referring tart therapy) every 6 months to Referring s, and biologic	submit results from g Physician o continue therapy) g Physician	within 12 months	to start and annually to continue therapy)		
			Reason for D/C:				
Medication Failed:							
Medication Failed:  Medication Failed:	Dates of Treatment Dates of Treatment			ason for D/C: ason for D/C:			
modication i alicu.	Dates Of Heatilletil		Re	accirioi D/C.			